Leprosy hasn't gone away: Uganda logged 1,935 new cases in five years

Leprosy is far from finished in Uganda, where national surveillance recorded 1,935 new cases between 2020 and 2024 with no measurable decline over the five years, according to an analysis published in July 2026 [s1]. One in five patients already had visible, irreversible disability by the time they were diagnosed — a sign that a curable, ancient disease is still being caught too late [s1].

That local stall sits against a global picture of steady, decades-long retreat. A separate secondary analysis of the Global Burden of Disease Study, covering 204 countries, found the age-standardised incidence rate of leprosy falling worldwide from 1990 to 2021, with an average annual percent change of -3.301, and a matching decline in the disability burden of -2.638 [s2]. The two findings are not in conflict; they are the point. Leprosy is being pushed down globally but persists stubbornly in specific places, and the endgame is fought in those pockets, not in the global average.

What Uganda's numbers show

The Ugandan study drew on routine national data from the District Health Information System 2, adding up newly diagnosed cases from 2020 to 2024 and mapping them by region and district [s1]. Overall incidence worked out to 8.8 per 1,000,000 population, and, tested formally, showed no significant trend across the period (p = 0.89) [s1].

The composition of those cases is what worries the authors. Multibacillary disease — the more infectious form, carrying a higher bacterial load — accounted for 86% of cases, and 21% of patients presented with Grade 2 Disability, meaning visible damage such as clawed hands or eye involvement already present at diagnosis [s1]. Children aged 15 and under made up 14% of cases, consistently above Uganda's national elimination target of under 3% and neither rising nor falling significantly over the five years (p = 0.069) [s1]. The Grade 2 Disability proportion likewise held steady (p = 0.14) [s1].

Each of those figures points the same way. A high share of multibacillary and paediatric cases indicates active, ongoing transmission rather than a tail of old infections being cleared, and a high disability share indicates diagnostic delay — patients reaching the health system only after nerve damage has set in [s1].

Where it concentrates

The burden is not spread evenly. Spatial analysis put persistently high incidence in the West Nile region, where 9 of 13 districts carried the heaviest disease load, with intermittently elevated disability proportions in the Teso and Ankole regions [s1]. That clustering is the practical target: the World Health Organization's Towards Zero Leprosy strategy aims for zero new infections and zero new Grade 2 Disability by 2030, and Uganda's own plan sets thresholds of under 3% child cases and under 5% disability — all of which the current data miss [s1].

Why the last mile is the hard part

Leprosy has a long history of premature victory declarations. Because it is curable with multidrug therapy and its overall numbers are low, it is easy to treat as solved — but the global decline the GBD analysis documents was uneven, strongest in high-incidence super-regions such as South Asia, Sub-Saharan Africa and Latin America and the Caribbean, and closely tracked each country's broader healthcare access and quality [s2]. Where health systems are strong, cases fall fast; where they are weak, transmission smoulders on, in children as well as adults [s2].

Uganda's flat five-year trend is a reminder that elimination is not self-executing. It depends on the unglamorous work of contact tracing and active case-finding in the specific districts still carrying the disease — the same last-mile logic that governs other neglected tropical diseases, from onchocerciasis to trachoma, where the final push is always the slowest [s1].

This article is informational and is not medical advice.

Sources

• [s1] "Temporal and spatial patterns of Leprosy in Uganda, 2020–2024: A nationwide surveillance analysis," PLOS Neglected Tropical Diseases, 2 July 2026. https://doi.org/10.1371/journal.pntd.0014450
• [s2] "Global trends in leprosy-related incidence and disease burden from 1990 to 2021: A secondary analysis of the Global Burden of Disease Study," Journal of Infection and Public Health, 27 August 2026. https://doi.org/10.1016/j.jiph.2026.103349